Inherent Biosciences
Inherent Biosciences is an AI-driven molecular diagnostics company that develops epigenetic sperm quality tests, marketed under its Path Fertility division as SpermQT and NOA Guide, for fertility clinics, self-insured employers, and men facing infertility or azoospermia.
- Company typePrivate
- Founded2021
- HeadquartersSalt Lake City, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Inherent Biosciences does
Inherent Biosciences is a molecular diagnostics company that develops and commercializes AI-driven epigenetic tests for male reproductive health, operating primarily through its Path Fertility division. The company's core technology is an epigenetic platform that uses machine learning to analyze DNA methylation patterns across 10,000+ gene promoters and 1,200+ sperm-function genes, categorizing sperm as excellent, normal, or abnormal to predict fertility outcomes not identified by standard semen analysis (which has only ~15% sensitivity). Tests are physician-ordered, use at-home specimen collection kits, and are processed in a CAP-accredited, CLIA-certified laboratory.
The company's commercial products are SpermQT (launched October 2021), an epigenetic sperm quality test validated on more than 2,000 semen samples with 84% sensitivity for predicting need for IVF, and NOA Guide (launched January 2026), a non-invasive diagnostic for men with non-obstructive azoospermia that analyzes cell-free DNA in seminal fluid to predict the likelihood of successful sperm retrieval during micro-TESE procedures. Real-world evidence from 537 couples across 10 fertility clinics shows a 0% IUI pregnancy rate for men with abnormal SpermQT versus 22% for normal SpermQT, and a 15.1% IUI live birth rate for poor-quality sperm versus 43.6% for excellent-quality sperm.
Revenue is generated primarily through one-time diagnostic test fees plus a longer-term licensing/royalty roadmap into therapeutics, sold via direct sales to fertility clinics, employer fertility benefit programs (Walmart through Kindbody plus 31 additional employer contracts), a global distribution partnership with Sapyen, an IVF-clinic channel partnership with Genomic Prediction, and direct-to-consumer telehealth through Posterity Health. Pricing is not publicly disclosed; comparable consumer kits start at $149. The company is venture-backed (Series A led by Propel Bio Partners in September 2022; seed led by Morning Star Foundation in February 2021) and has secured approximately $2.26M in NIH and NSF non-dilutive grant funding, including a $1.9M NIH Fast-Track SBIR award. Inherent Biosciences is headquartered in Salt Lake City, Utah, operates with 1–10 employees, and is pursuing a $1B fertility market opportunity at a 4.5% CAGR.
Inherent Biosciences firmographics
Firmographics- Name
- Inherent Biosciences
- Legal name
- Inherent Biosciences, Inc.
- Website
- https://inherentbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Inherent Biosciences is an AI-driven molecular diagnostics company that develops epigenetic sperm quality tests, marketed under its Path Fertility division as SpermQT and NOA Guide, for fertility clinics, self-insured employers, and men facing infertility or azoospermia.
- Ownership category
- akta.pro rank
Inherent Biosciences industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Prenatal Testing Laboratories (HLAFAMAH)
Keywords
Where Inherent Biosciences is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Inherent Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Diagnostic Testing Services: Revenue from commercial diagnostic tests including SpermQT and NOA Guide. Tests are physician-ordered with at-home specimen collection kits shipped to CAP accredited and CLIA certified laboratories for analysis. Results reported as risk categories to guide fertility treatment decisions.
- Pipeline - Therapeutics Development: The company states it is developing diagnostic tools—and eventually therapeutics—that unlock personalized insights and offer actionable guidance to healthcare providers and their patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Sapyen DNA Methylation Test |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
Inherent Biosciences product offering
Product offeringCore offering
Inherent Biosciences is a molecular diagnostics company that develops and commercializes epigenetic diagnostic tests for male reproductive health. Its primary commercial offering, SpermQT, is an epigenetic sperm quality test that analyzes DNA methylation patterns to assess male fertility, sold through the Path Fertility division. The company is also developing NOA Guide, a diagnostic aid for non-obstructive azoospermia, and operates a proprietary AI/ML-driven platform that profiles epigenetic patterns from semen samples.
Product overview
Inherent Biosciences offers a portfolio of epigenetic diagnostic tests for male reproductive health, marketed primarily under the Path Fertility brand. The core products include SpermQT, an AI-powered epigenetic sperm quality test that analyzes DNA methylation patterns to predict fertility outcomes and guide treatment decisions, and NOA Guide, a diagnostic for men with non-obstructive azoospermia. The company also provides scientific research consulting services. The products are designed to address gaps in male fertility diagnosis where standard semen analysis is insufficient.
Differentiator
Problem solved
Functional benefit
Brands
- SpermQT: Epigenetic sperm quality test that predicts poor fertility outcomes not identified with standard semen analysis, categorizing sperm as excellent, normal, or abnormal based on epigenetic patterns
- NOA Guide
Products and services
- SpermQT
- NOA Guide
Quantifiable outcome
- 84% sensitivity in predicting need for IVF treatment based on validation data from over 2,000 semen samples
- +6 more outcomes
Companies that use Inherent Biosciences
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Inherent Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Inherent Biosciences partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- SapyencoreGlobal partnership to deliver first clinically validated DNA methylation test for male fertility worldwide. Sapyen's patent-pending SPX72 medium extends sperm viability from 1 hour to 3 days, enabling home collection and shipping. Test analyzes methylation patterns across 1,200+ genes. Implementation underway across major IVF networks.
- Walmart / KindbodycoreSpermQT added to Walmart's Fertility and Family-Building Benefits for associates managed by Kindbody. Established through definitive agreement with Walmart's Fertility Benefit Provider Kindbody. Walmart chose Kindbody as Center of Excellence for fertility care.
- Fuel HealthTech AcceleratorminorCompleted Fuel HealthTech Accelerator in Bentonville, Arkansas. Program provided mentorship, industry connections, and feedback for refining Path Fertility product offerings. Milestones included developing key features of SpermQT and establishing strategic partnerships with healthcare providers.
- Genomic PredictioncoreComprehensive commercial partnership integrating Inherent Biosciences' Epigenetic Sperm Quality Test (SpermQT) into Genomic Prediction's suite of clinical laboratory tests. Genomic Prediction, a leader in pre-implantation genetic testing, adds SpermQT to its LifeView tests for IVF patients.
- Seattle Sperm BankminorCollaboration presenting novel approach to qualifying sperm donors. Poster presentation at American Society of Andrology Annual Meeting exploring use of SpermQT to qualify more sperm donor samples for IUI procedures.
- Posterity HealthcorePartnership enables Inherent to offer Path Fertility branded SpermQT directly to consumers. Patients can order SpermQT and receive virtual telehealth consultation from male fertility specialists. Comprehensive IUI Assessment includes semen analysis, SpermQT, and telehealth consultation.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Inherent Biosciences competitors and assessment
Company assessmentBroad incumbents
- Natera: Public molecular diagnostics company with established reproductive genetic tests (e.g., Empower, Spectrum). Operates at scale in the same IVF clinic channel and could expand into male-factor workups.
- Vitrolife: Global IVF solutions company offering media, consumables, and genomic services across the assisted reproduction workflow. Serves the same fertility clinics and could broaden into epigenetic diagnostics.
- Hamilton Thorne: Provider of precision instruments, consumables, and software for the IVF and animal breeding markets, including CASA semen analysis systems. Supplies the same andrology labs as a category incumbent.
- Quest Diagnostics: Largest US clinical reference laboratory with extensive reproductive and genetic testing menu. CLIA infrastructure and national sales force pose both a partnership opportunity and a competitive threat.
- LabCorp (Laboratory Corporation of America): National CLIA-certified reference laboratory running the full menu of reproductive and genetic tests. Operates the same CAP/CLIA testing infrastructure that processes SpermQT specimens and could commercialize a competing assay.
- CooperSurgical: Large diversified fertility and women's health diagnostics and medical device company. Sells established semen analysis instruments and reagents to the same fertility clinics that order SpermQT; could develop or acquire a competing epigenetic test.
Direct peers
- Genomic Prediction: Clinical laboratory specializing in pre-implantation genetic testing for IVF. Commercial integration partner that bundles SpermQT with its LifeView tests; serves the same reproductive endocrinology customers.
- Posterity Health: Male fertility telehealth and clinical care provider that pairs patients with SpermQT testing as part of a comprehensive IUI assessment. Operates in the same male-factor infertility diagnostic pathway.
- Sapyen: Australian male fertility diagnostics company offering at-home DNA methylation and semen analysis testing. Direct distribution partner for Inherent's SpermQT biomarkers via its SPX72 home-collection platform, and also offers its own competing methylation test.
Emerging players
- Seattle Sperm Bank: Sperm donor cryobank collaborating with Inherent on epigenetic donor qualification. Comparable use case (sperm quality assessment) and an emerging channel for sperm epigenetic biomarker adoption.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Inherent Biosciences social profiles
Digital presenceInherent Biosciences compliance and trust
Trust signalCompliance2 records
Inherent Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inherent Biosciences leadership team
Management profileNumber of profiles
Profiles6 records
Inherent Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Inherent Biosciences funding detail
Funding detailFunding overview
Funding rounds6 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inherent Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inherent Biosciences
What does Inherent Biosciences do?
Inherent Biosciences is a molecular diagnostics company that develops and commercializes epigenetic diagnostic tests for male reproductive health. Its primary commercial offering, SpermQT, is an epigenetic sperm quality test that analyzes DNA methylation patterns to assess male fertility, sold through the Path Fertility division. The company is also developing NOA Guide, a diagnostic aid for non-obstructive azoospermia, and operates a proprietary AI/ML-driven platform that profiles epigenetic patterns from semen samples.
Is Inherent Biosciences a public or private company?
Inherent Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inherent Biosciences founded?
Inherent Biosciences was founded in 2021. It employs 1 to 10 people.
Where is Inherent Biosciences based?
Inherent Biosciences is headquartered in Salt Lake City, United States, in the North America region.
How does Inherent Biosciences make money?
Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are pipeline - Therapeutics Development.
Who are Inherent Biosciences's main competitors?
Broad incumbents on record are Natera, Vitrolife, Hamilton Thorne, Quest Diagnostics, LabCorp (Laboratory Corporation of America) and CooperSurgical. Direct peers are Genomic Prediction, Posterity Health and Sapyen. Seattle Sperm Bank is listed as an emerging player.
Does Inherent Biosciences have an API?
No public API is recorded for Inherent Biosciences.
What industry is Inherent Biosciences in?
Inherent Biosciences's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 621511 and its SIC code is 2835.